M
Matthew J. Hartwell
Researcher at Icahn School of Medicine at Mount Sinai
Publications - 19
Citations - 389
Matthew J. Hartwell is an academic researcher from Icahn School of Medicine at Mount Sinai. The author has contributed to research in topics: Medicine & Femoroacetabular impingement. The author has an hindex of 5, co-authored 9 publications receiving 246 citations.
Papers
More filters
Journal ArticleDOI
An early-biomarker algorithm predicts lethal graft-versus-host disease and survival
Matthew J. Hartwell,Umut Ozbek,Ernst Holler,Anne S. Renteria,Hannah Major-Monfried,Pavan Reddy,Mina Aziz,William J. Hogan,Francis Ayuk,Yvonne A. Efebera,Elizabeth O. Hexner,Udomsak Bunworasate,Muna Qayed,Rainer Ordemann,Matthias Wölfl,Stephan Mielke,Attaphol Pawarode,Yi Bin Chen,Steven M. Devine,Andrew C. Harris,Madan Jagasia,Carrie L. Kitko,Mark R. Litzow,Nicolaus Kröger,Franco Locatelli,George Morales,Ryotaro Nakamura,Ran Reshef,Wolf Rösler,Daniela Weber,Kitsada Wudhikarn,Gregory A. Yanik,John E. Levine,James L.M. Ferrara +33 more
TL;DR: A biomarker algorithm based on a blood sample taken 7 days after HCT can consistently identify a group of patients at high risk for lethal GVHD and NRM.
Journal ArticleDOI
MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD
Hannah Major-Monfried,Anne S. Renteria,Attaphol Pawarode,Pavan Reddy,Francis Ayuk,Ernst Holler,Yvonne A. Efebera,William J. Hogan,Matthias Wölfl,Muna Qayed,Elizabeth O. Hexner,Kitsada Wudhikarn,Rainer Ordemann,Rachel Young,Jay Shah,Matthew J. Hartwell,Mohammed S. Chaudhry,Mina Aziz,Aaron Etra,Gregory A. Yanik,Nicolaus Kröger,Daniela Weber,Yi-Bin Chen,Ryotaro Nakamura,Wolf Rösler,Carrie L. Kitko,Andrew C. Harris,Michael A. Pulsipher,Ran Reshef,Steven Kowalyk,George Morales,Ivan J. Torres,Umut Ozbek,James L.M. Ferrara,John E. Levine +34 more
TL;DR: MAGIC biomarker probabilities generated after 1 week of systemic treatment of GVHD predict long-term outcomes in steroid-resistant GV HD better than clinical criteria and should prove useful in developing better treatment strategies.
Journal ArticleDOI
The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease
Hrishikesh K. Srinagesh,Umut Ozbek,Urvi Kapoor,Francis Ayuk,Mina Aziz,Kaitlyn Ben-David,Hannah K. Choe,Zachariah DeFilipp,Aaron Etra,Stephan A. Grupp,Matthew J. Hartwell,Elizabeth O. Hexner,William J. Hogan,Alexander B. Karol,Stelios Kasikis,Carrie L. Kitko,Steven Kowalyk,Jung-Yi Lin,Hannah Major-Monfried,Stephan Mielke,Pietro Merli,George Morales,Rainer Ordemann,Michael A. Pulsipher,Muna Qayed,Pavan Reddy,Ran Reshef,Wolf Rösler,Karamjeet S. Sandhu,Tal Schechter,Jay Shah,Keith Sigel,Daniela Weber,Matthias Wölfl,Kitsada Wudhikarn,Rachel Young,John E. Levine,James L.M. Ferrara +37 more
TL;DR: A MAP measured before and after treatment of acute GVHD is a response biomarker that predicts long-term outcomes more accurately than change in clinical symptoms and may function as a useful end point in clinical trials.
Journal ArticleDOI
The MAGIC Algorithm Probability (MAP) Is a Validated Response Biomarker of Treatment for Acute Graft-Versus-Host Disease
Hrishikesh K. Srinagesh,Umut Ozbek,Urvi Kapoor,Francis Ayuk,Mina Aziz,Kaitlyn Ben-David,Hannah Choe,Zachariah DeFilipp,Aaron Etra,Stephan A. Grupp,Matthew J. Hartwell,Elizabeth O. Hexner,William J. Hogan,Alexander B. Karol,Stelios Kasikis,Carrie L. Kitko,Steven Kowalyk,Hannah Major-Monfried,Jung-Yi Lin,Stephan Mielke,Pietro Merli,George Morales,Rainer Ordemann,Michael A. Pulsipher,Muna Qayed,Pavan Reddy,Ran Reshef,Wolf Roesler,Karamjeet S. Sandhu,Tal Schechter,Jay Shah,Keith Sigel,Daniela Weber,Matthias Wölfl,Kitsada Wudhikarn,Rachel Young,John E. Levine,James L.M. Ferrara +37 more
TL;DR: The MAP is, to the authors' knowledge, the first laboratory test validated as a response biomarker for acute GVHD treatment and more accurately predicts survival than clinical response after 28 days of treatment.
Journal ArticleDOI
Disease risk and GVHD biomarkers can stratify patients for risk of relapse and nonrelapse mortality post hematopoietic cell transplant.
Mina Aziz,Jay Shah,Urvi Kapoor,Christina Dimopoulos,Sarah Anand,Allan Augustine,Francis Ayuk,Mohammed S. Chaudhry,Yi-Bin Chen,Hannah K. Choe,Aaron Etra,Stephanie Gergoudis,Matthew J. Hartwell,Elizabeth O. Hexner,William J. Hogan,Carrie L. Kitko,Steven Kowalyk,Nicolaus Kröger,Pietro Merli,George Morales,Ryotaro Nakamura,Rainer Ordemann,Michael A. Pulsipher,Muna Qayed,Ran Reshef,Wolf Rösler,Tal Schechter,Elisabeth Schreiner,Hrishikesh K. Srinagesh,Matthias Wölfl,Kitsada Wudhikarn,Gregory A. Yanik,Rachel Young,Umut Ozbek,James L.M. Ferrara,John E. Levine +35 more
TL;DR: Patients who had not developed GVHD and who possessed a low MAP were at much higher risk for relapse than severe GV HD and NRM, and this difference was even more pronounced in patients with a high disease risk index.